Resiquimod

Resiquimod has been studied in 3 papers since 2022: none in people yet, 2 in animals, 1 in cells; 1 in the past year. The research so far is in animals and cells. The newest paper, May 20, 2026: “Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy”.

Intervention

3 papers study it1 more mentions it2 findingsUpdated

PubChemChEBIMeSH

See all 4 papers on resiquimod

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Center for Advancing Translational Sciences and 3 more
  • Animals2
  • Cells1

What did studies of resiquimod find?

2

Studies of resiquimod measured 2 outcomes: virus-specific IgG antibody and virus-specific IgM antibody.

Virus-specific IgG antibody

upin C. aethiops1

1 study
  1. Resiquimod increases virus-specific IgG antibody in C. aethiops after boosting.

    “there were significant increases in virus-specific IgG after boosting selectively in the IPR8-R848 vaccinated animals.”

    Animalsafter boosting

    Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates

    Vaccines

More on Virus-specific IgG antibody

Virus-specific IgM antibody

upin C. aethiops1

1 study
  1. Resiquimod increases virus-specific IgM antibody in C. aethiops.

    “We observed increases in the level of circulating virus-specific IgM antibody 10 days following primary vaccination in AGM that were vaccinated with IPR8-R848, but not IPR8 alone.”

    Animals10 days

    Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates

    Vaccines

More on Virus-specific IgM antibody

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months